摘要
目的分析美托洛尔联合曲美他嗪治疗冠心病心力衰竭临床疗效。方法整群选取从2015年1月—2016年1月该院收治的156例冠心病心力衰竭患者,随机分为对照组(80)与治疗组(76),对照组采取常规药物治疗,治疗组在对照组基础上采用美托洛尔联合曲美他嗪治疗,对比两组疗效。结果治疗后,治疗组LVEF(51.56±2.74)、LVESD(30.75±3.64)、LVEDD(51.27±4.28)、SBP(120.08±6.32)、DBP(80.74±5.35)、HR(77.65±7.12)指标改善优于对照组LVEF(44.08±3.57)、LVESD(37.08±3.52)、LVEDD(58.23±5.31)、SBP(131.34±8.45)、DBP(88.17±6.48)、HR(86.34±6.24)(P<0.05)。对照组总有效率为75.00%,治疗组为92.11%,治疗组明显高于对照组(P<0.05)。对照组不良反应发生率为12.50%,治疗组为10.52%,两组差异无统计学意义(P>0.05)。结论对冠心病心力衰竭采用美托洛尔联合曲美他嗪治疗,安全有效,具有临床应用价值。
Objective To analyze the metoprolol combined with trimetazidine of trimetazidine in patients with coronary heart disease and heart failure clinical curative effect. Methods Group selection a total of from January 2015 — January 2016156 cases of coronary heart disease patients with heart failure, were randomly assigned to control group(n = 80) and treatment group(76), the control group take routine treatment, treatment group in the control group based on the use of metoprolol combined with trimetazidine treatment, the curative effects were compared between two groups. Results After treatment,treatment group LVEF(51.56 ±2.74)、LVESD(30.75 ±3.64)、LVEDD(51.27 ±4.28)、SBP(120.08 ±6.32)、DBP(80.74 ±5.35)、HR(77.65±7.12)indicators better than control group LVEF(44.08±3.57)、LVESD(37.08±3.52)、LVEDD(58.23±5.31)、SBP(131.34±8.45)、DBP(88.17±6.48)、HR(86.34±6.24)(P<0.05). In control group, the total effective rate was 75.00%. The treatment group was 92.11%, the treatment group was significantly higher than that of control group(P<0.05). In the control group, the incidence rate of adverse reaction was 12.50%, the treatment group was 10.52%, two groups no significant difference(P >0.05). Conclusion On coronary heart disease and heart failure with metoprolol combined with trimetazidine treatment, safe and effective, has the value of clinical application.
出处
《中外医疗》
2016年第29期118-120,共3页
China & Foreign Medical Treatment
关键词
冠心病
心力衰竭
美托洛尔
曲美他嗪
疗效
Coronary heart disease
Heart failure
Metoprolol M
Sibutramine trimetazidine
Curative effect
